Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
0.8600
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Enlivex Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2016 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Net Income
-15.01-29.07-31.06-14.47-11.82
Upgrade
Depreciation & Amortization
0.550.840.780.550.29
Upgrade
Loss (Gain) From Sale of Assets
0.884.22---
Upgrade
Loss (Gain) From Sale of Investments
-0.56-0.341.98-5.59-
Upgrade
Stock-Based Compensation
2.071.952.712.910.67
Upgrade
Other Operating Activities
0.30.70.830.410.17
Upgrade
Change in Accounts Payable
-0.02-1.121.170.440.04
Upgrade
Change in Other Net Operating Assets
-1.2-0.7-0.36-1.8-0.34
Upgrade
Operating Cash Flow
-13.01-23.52-23.95-17.54-11.01
Upgrade
Capital Expenditures
-0.1-0.24-8.12-1.63-1.02
Upgrade
Sale of Property, Plant & Equipment
2.290.13---
Upgrade
Investment in Securities
6.87-25.8770.65-36.78-19.96
Upgrade
Investing Cash Flow
9.06-25.9762.52-38.41-20.98
Upgrade
Issuance of Common Stock
7.10.510.1565.4435.58
Upgrade
Other Financing Activities
-0.65-0.15--4.46-2.5
Upgrade
Financing Cash Flow
6.450.360.1560.9833.08
Upgrade
Foreign Exchange Rate Adjustments
----0.410.39
Upgrade
Net Cash Flow
2.51-49.1338.724.621.49
Upgrade
Free Cash Flow
-13.11-23.76-32.08-19.17-12.03
Upgrade
Free Cash Flow Per Share
-0.64-1.28-1.74-1.07-0.91
Upgrade
Levered Free Cash Flow
-5.41-17.77-18.68-10.19-5.87
Upgrade
Unlevered Free Cash Flow
-5.41-17.77-18.68-10.19-5.87
Upgrade
Change in Net Working Capital
-1.84.6-2.08-0.03-0.31
Upgrade
Updated Nov 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q